Nivolumab
ALK Gene Rearrangement
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the ALK Gene Rearrangement cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Crizotinib ECOG-ACRIN Cancer Research Group | Phase 3 | B |
Binimetinib University of California, San Francisco | Phase 1 | CC |
Brigatinib University of California, San Francisco | Phase 1 | CC |
Ipilimumab M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →